Ipratropium/Salbutamol Orion

Salbutamol/Ipratropium bromide, the active ingredient in Ipratropium/Salbutamol Orion, is a bronchodilator presented as a combination formulation for oral use. It relaxes airway smooth muscle and inhibits vagally mediated bronchoconstriction, providing symptom relief for patients with asthma and chronic obstructive pulmonary disease (COPD).

GNH USA supplies Ipratropium/Salbutamol Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium/Salbutamol Orion is a bronchodilator used in respiratory disorders to improve airway patency.

Asthma: enhances bronchodilation and reduces acute symptoms. Chronic obstructive pulmonary disease (COPD): decreases bronchospasm and improves airflow. Exercise‑induced bronchoconstriction: provides rapid relief of exercise‑related airway narrowing.

Adverse reactions may occur with any bronchodilator therapy.

Common Side Effects: - Tremor: mild shaking of hands or limbs. - Palpitations: sensation of rapid or irregular heartbeat. - Dry mouth: reduced salivary flow. - Cough: irritation of the throat. - Headache: mild to moderate intensity. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening of breathing difficulty. - Cardiac arrhythmia: irregular heart rhythm requiring medical attention. - Hypersensitivity reactions: rash, itching, or swelling. - Severe tachycardia: markedly elevated heart rate. - Angioedema: swelling of lips, tongue, or throat. - Hyperglycaemia: elevated blood glucose levels in susceptible individuals.

Use this medication only under medical supervision and monitor for adverse events.

Pregnancy: discuss risks with a healthcare provider before use. Breastfeeding: evaluate potential exposure to the infant. Cardiovascular disease: use cautiously in patients with heart conditions. Diabetes: monitor blood glucose as β2‑agonists may affect levels. Thyroid disorders: consider dose adjustments if hyperthyroidism is present. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Drug interactions can modify the therapeutic effect or increase adverse risks.

Major Interactions (Avoid): - Non‑selective β‑blockers: may diminish bronchodilator response. - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension. - Diuretics: potential for hypokalaemia augmentation.

Moderate Interactions (Monitor Closely): - Theophylline: increased risk of tachyarrhythmia. - Corticosteroids: may enhance systemic effects. - Anticholinergic agents: additive dry‑mouth effects. - Beta‑agonist inhalers: risk of cumulative cardiovascular stimulation.